Investigación sobre el cáncer de Providence destacada en ESMO20

Providence cancer research highlighted at ESMO20

Providence Cancer Institute joins oncology professionals around the world for ESMO Virtual Congress 2020, the annual meeting of the European Society for Medical Oncology, held online from September 14 through October 18. The virtual meeting will present promising new developments aimed at improving cancer patient care. 

Several abstracts with contributions by investigators at Earle A. Chiles Research Institute, a division of Providence Cancer Institute, are selected for presentation at the conference.

Lung cancer and early phase immunotherapy research by Rachel E. Sanborn, M.D., associate member and director, Phase I Clinical Trials Program, and co-director, Providence Thoracic Oncology Program, are highlighted in various abstracts, and a pilot study in head and neck cancer features contributions by Rom S. Leidner, M.D., co-director, Providence Head and Neck Cancer Clinic.

View a list of the abstracts below, with links to additional information. 

Proferred Paper Sessions 

Non-Small Cell Lung Cancer (NSCLC) Metastatic 1

Abstract 1258O: Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. B.C. Cho, K.H. Lee, E.K. Cho, D.W. Kim, J.S. Lee, J.Y. Han, S.W. Kim, A. Spira, E. Haura, J. Sabari, R. Sanborn, J. Bauml, J. Gomez, P. Lorenzini, J. Infante, J.

Presented September 20, 2020 at 14:25-16:05 CEST on Channel 1.

Investigational Immunotherapy

Abstract 1020O: A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours. Sharma MR, Sanborn RE, Cote GM, Bendell J, S Kaul, Chen F.

Presented September 20, 2020 at 14:25-16:05 CEST on Channel 2.

Mini Oral Sessions 

Non Small Cell Lung Cancer (NSCLC) Metastatic

Abstract 1260MO: Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial. G Giaccone…RE Sanborn et al.

Presented September 18 and available on demand.

ePoster Sessions

Trials in Progress

Abstract 976TiP: SPEARHEAD-2 trial design: A Phase 2 pilot trial of ADP-A2M4 in combination with pembrolizumab in patients with recurrent or metastatic head and neck cancer (r/m HNSCC). Cohen E, Dunn L, Neupane P, Gibson M, Leidner R, Savvides P, Hyland N, Trivedi T, Dudley M, Biswas S, Williams D, Norry E.

Abstract 1074TiP: SGNTGT-001: A phase I study of SGN-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies. E. Garralda, R.E. Sanborn, A.R. Minchom, D. Davar, G. Curigliano, V. Ribrag, A. Mehta, F. Foss, P. Garfin, S. Ansell.

Presented September 17 and available on demand.

Follow us on Twitter and Facebook for the latest news, articles and more. To learn more about our comprehensive care for patients with lung and head and neck cancers, visit Providence Thoracic Oncology Program and Providence Head and Neck Cancer Program.

New trials available at Earle A. Chiles Research Institute for patients with human epidermal growth factor receptor 2 positive (HER2+) colorectal cancer and patients with cholangiocarcinoma.
In honor of Social Work Month we recognize the incredible contributions of oncology social workers.
A new trial offered at Providence Cancer Institute is enrolling patients with early-stage HR-positive and HER2-negative breast cancer.
As part of an international data-sharing consortium of leading cancer centers, Providence Cancer Institute and Swedish Cancer Institute work together to provide genomic data to Project GENIE.
Powered by GlobalLink OneLink SoftwarePowered By OneLink